Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Major Win for Patients as Brazil Rejects a Key Patent on Gilead Hepatitis C Drug and European Court of Justice Opinion Denies Patent Extension to Gilead’s HIV Drug
Tahir Amin: Increasing Access to Affordable HIV Drugs Through Patent Opposition
A Supreme Court victory for lowering drug prices
Tahir Amin: Transparency in Drug Pricing
Tahir Amin: Pay-for-Delay Settlements and Patient Access
Tahir Amin: The Role of Advocacy Groups in the Patent System
Gilead patent for its Sovaldi hepatitis C drug is rejected in Ukraine
Global Access Expert Rohit Malpani Joins I-MAK’s Growing Team to Solve Drug Patent Problem
Ready to Leave the Private Sector for Public Service? Read This First.
Another reason to visit Egypt: Europe’s high drug prices